Abstract: The aim of the study was to evaluate the risk of chemical cross-contamination between preparations of cytotoxic drugs performed in hospital pharmacy. Simulation of handling process errors was performed with two selected tracers, thiamine and retinol to mimic hydrophilic and lipophilic cytotoxic drugs. Four types of handling errors were simulated: errors associated with the re-use of a disposable transfer device: syringe, spike and needle and errors associated with surface contamination such as the use of a contaminated pad. The results show rates of contamination above the limit of quantification with the re-use of a syringe, a needle or a spike. For example, with the thiamine solution at 50 mg/ml final concentration, the re-use of a spike led to a contamination of approximately 100 µl equivalent to 5 mg. By contrast, the use of a surface contaminated pad failed to detect a cross-contamination. Cross-contamination related to a contamination of surface by a cytotoxic drug represents a low risk. However, the re-use of a single medical device due to handling human error led to quantifiable risk of cross-contamination. Furthermore, this type of error is very difficult to detect and may be frequent enough to have potential impact on patient.
Introduction
Centralized preparation of injectable cytotoxic drugs in hospital pharmacy is implemented to protect the final product and to protect handlers against exposure to hazardous drugs. Due to this centralization more than 50 drugs are used simultaneously in a contained environment (laminar airflow hoods or isolators). The risk of cross contamination is thus theoretically important and the potential risk for patients is varying according to specific toxicity of drugs. Some of them, in particular the monoclonal antibodies, have a lower toxicity and are not included in the NIOSH or IARC lists (1, 2) . The risk for patients be that they could be then to be exposed to low levels of drugs more toxic than the drugs that they should receive.
Several studies have shown that external contamination cannot be excluded; for example, some studies indicated that vials delivered from pharmaceutical companies may be contaminated on the outside surface with the cytotoxic drug (3) (4) (5) . Other studies have shown that aseptic manipulation using a syringe and needle technique resulted in environmental contamination which can be minimized by closed-transfer systems. Nevertheless, the internal contamination may be not significant due to the use of closed transfer method for the preparation of hazardous drugs (6) (7) (8) (9) (10) .
However, human errors during handling process cannot be excluded and could lead to cross contamination. The objective of the study was therefore to assess the risk of cross-contamination between different cytotoxic preparations by simulating the potential errors of preparation with tracer solutions. We considered in our work the most commonly worldwide used process which is manual aseptic preparation and considered that the facility where the preparations may be performed (i. e. biosafety cabinet or isolator) will hardly impact on the improper reuse of devices by operators.
Materials and methods

Materials
Tracers solutions was produced from retinol (Vitamine A Nepalm 100,000 UI / 2 ml, Haupt pharma livron, Livron sur Drôme, France) diluted in Water For Injection (WFI) at the final concentration of 6 mg/ml and from thiamine chlorhydrate (Cooper, Melun, France) diluted in WFI at the final concentration of 50 mg/ml.
The handling material used were syringes (Becton Dickinson, Drogheda, Ireland), needles (Becton Dickinson, Drogheda, Ireland), pads (Tetra, Annonay, France) and spikes (ICU medical, Hannover, Germany).
The HPLC system consisted of a pump (L-2130, VWRHitachi, Tokyo, Japan) and a diode array detector (L2455, VWR-Hitachi, Tokyo, Japan). The chromatographic peaks were analyzed using the software EZChrom elite (VWRHitachi, Tokyo, Japan).
For retinol, the column used was a Hypersil C8 (250 mm × 4.6 mm, id = 5 µm) (Shandon, Eastmore, United kingdom). The mobile phase consisted of methanol (Sigma-Aldrich, Steinheim, Germany)/dichloromethane (Merck, Darmstadt, Germany) (95/5 v/v). The volume of injection was 50 µl. The flow rate was 1 ml/ min. The peaks were analyzed at a wavelength of 325 nm.
For thiamine, the column used was a C18 Nucleodur Gravity (Macherey-Nagel, Düren, Germany) (250 mm × 4.6 mm, id = 5 µm). The mobile phase consisted of a 0.05 M phosphate buffer (sodium phosphate dibasic, Sigma-Aldrich, Steinheim, Germany) pH = 2.9/Acetonitrile (Sigma-Aldrich, Steinheim, Germany) (99/1 v/v). The volume of injection was 50 µl. The flow rate was 1 ml/ min. The peaks were analyzed at a wavelength of 254 nm.
Methods
Choice of tracers
Tracers which simulate the physicochemical characteristic of cytotoxics were used in place of cytotoxic drugs to minimize the risk of toxicity.
The choice of tracers was based on a review of the physicochemical properties of most cytotoxic drugs. This review was conducted using the databases Toxnet (11), Drugbank (12) and the European pharmacopeia (13) . The characteristics selected were the log P and the solubility in water. In a second step tracers which have similar physicochemical characteristics were investigated. The selected tracers exhibiting less toxicity were retinol and thiamine.
Usual handling process
The pad is used in the process to limit the dispersion in the environment of droplets at the time of connection or disconnection of the different transfer devices (syringe, needle and spike). The syringe is used for transfer and withdrawal of the drug from vial to final content (e. g. bag). To ensure homogenization of the drug in the final bag, five flushes with the same syringe is applied. The needle and the spike are used for withdrawing liquids from the vials and transferring to final contents.
Selected handling errors
The whole team involved in the production of chemotherapy (pharmacists, operators and control technicians) considered possible sources of cross-contamination coming from human errors.
Four types of handling errors were identified. Errors associated with the re-use of a disposable transfer device i. e. syringe, spike and needle, and errors associated with surface contamination such as a contaminated pad. Thus a total of six operators have carried out four types of simulations repeated three times. Each preparation was performed with two tracers simulating hydrophilic and lipophilic drugs.
The process performed to quantify the rate of crosscontamination related to the re-use of a disposable transfer device consisted of preparing a 5 ml syringe of tracer (thiamine or retinol) and then preparing a 5 ml placebo syringe of WFI with the same disposable transfer device (syringe, needle or spike). The process performed to quantify the level of cross-contamination due to a surface contamination has consisted in the contamination of a pad with a volume of 2 ml of tracers (retinol or thiamine) and then by the preparation of a syringe of WFI using the contaminated pad. The same process without the use of a tracer served as a control. The tracers were quantified in the placebo syringes of water. All operators involved in the simulation were previously trained and qualified for cytotoxic aseptic compounding.
The simulated area used was uncontrolled areas but was an easily cleanable working room.
Quantification of tracers
Tracers were quantified separately by HPLC. The validation of methods for the determination of retinol and thiamine was validated according to the criteria of SFSTP (14) and ICH (15) . For thiamine linearity was validated to 1-2,000 µg/ml. The coefficient of variation (CV) of repeatability was 2.12 %. The reproducibility CV was 2.75 %. The accuracy of the method was 96.2 % (IC : 91.2 -101 %). The limit of detection (LD) was 0.2 µg/ml.
The limit of quantification (LQ) was 1 µg/ml. For the retinol linearity was validated to 1-200 µg/ml. The CV of repeatability was 2.55 %. The reproducibility CV was 4.95 %. The accuracy of the method was 94.9 % (IC: 88.6-101 %). The LD was 0.3 µg/ml. The LQ was 1 µg/ml.
Statistical analysis
Statistical comparisons were performed between operators, tracers and critical cases using ANOVA statistical test.
Results
Tracer selection
Among all cytotoxic drugs, it is possible to differentiate them by their lipophilic affinity and solubility in water. Some drugs are hydrophilic and soluble in water like cisplatin, 5-Fluorouracile, or cyclophosphamide, others are lipophilic and poorly soluble in water like carmustine, docetaxel or paclitaxel (Table 1) .
In order to simulate the real cases, it was necessary to both select a lipophilic tracer and an hydrophilic one which can be diluted in aqueous solution.
We selected thiamine, hydrophilic and freely soluble in water and retinol, lipophilic and practically insoluble in water. In addition, retinol has the advantage of sharing the same adjuvant as paclitaxel i. e. polyoxylated castor oil. Tables 2 and 3 give the results of cross contamination levels obtained in the placebo syringes for the four simulation processes of handling errors with thiamine and retinol. To facilitate the comparison between the results, they are expressed by volume (µl) taking into account the concentrations of the solutions of thiamine (50 mg/ml) and retinol (6 mg/ml). The conversion in volume was carried out following two steps. First, by multiplying the concentration measured by HPLC by the volume of 5 ml of the placebo syringe using the formula C = m/V where C is concentration (µg/ml), m is the mass (µg) and V is the volume (ml). This allows to calculate an amount (µg) of tracer in the placebo syringe. This amount is subsequently transformed by volume taking into account the respective concentrations of thiamine or retinol using the same formula C = m/V. Whether by thiamine or retinol the results show rates of contamination above the limit of quantification with the re-use of a syringe, a needle or a spike ( Figure 1 ). In contrast, the use of contaminated pad failed to detect contamination above the threshold of quantification.
Cross contamination assessment
The results of the statistical analysis show that whatever the tracer and whatever the critical case there was no statistically significant difference between operators (Table 4) . Thus all operators were merged into a single homogeneous group.
For the tracers, there was no statistically significant difference with the re-use of a needle (p = 0.98), and pad. In contrast, a statistically significant difference was found with the syringe and the spike between retinol and thiamine (p < 0.001).
Finally, it has been shown that the four critical cases are not equivalent between themselves (statistically significant difference p < 0.001). Whatever the tracer, the risk of cross-contamination was in decreasing order spike > needle > syringe.
Using the experimental results obtained with the tracers, it can be extrapolated cross-contamination quantity for cytotoxic drugs using the following equation (Figure 2 ). For example, in case of inappropriate re-use 
For each operator, level of contamination is expressed in volume (µl) of mean ± standard deviation of three experiments (n = 3). Re-use of the same syringe for the following preparation. Re-use of the same needle for the following preparation.
d Re-use of the same spike for the following preparation.
e Use of a surface contaminated pad to perform the following preparation. LQ: limit of quantification. 
For each operator, level of contamination is expressed in volume (µl) of mean ± standard deviation of three experiments (n = 3). of a disposable medical device such as spike, the rate of cross-contamination may exceed 1 mg. The extrapolated rates calculated for the most common cytotoxic drugs are given in Table 5 .
Discussion
Our study showed that handling errors due to inappropriate re-use of single use devices i. e. syringe, needle spike are potential sources of cross-contamination. In contrast, surface chemical contamination of the working environment would be at low risk for cross-contamination. Despite the large surface contamination with cytotoxic drugs found on working surfaces (16) (17) (18) (19) (20) , the manufacturing process using only enclosed vials and transfer systems remaining in place throughout the duration of transfer according to good manufacturing guidelines (21) would dramatically limit transfer of contaminant from the outside to the inside of a preparation. This is confirmed by our study which was using a worst case surface contamination of 4 mg/cm 2 and 0.24 mg/cm 2 for thiamine and retinol respectively in comparison to real surface contamination usually found around 100 ng/cm 2 . We can safely conclude that surface contamination is unlikely involved in potential cross-contamination.
On the other hand, inappropriate re-use of a single use device cannot be excluded due to the human management of the preparation. Few studies investigated the error rate of injectable preparation when performed in hospital pharmacies. One study, in five hospital pharmacies in USA estimated a residual mean error rate of 9 % (6-10 %) (22) . More recently, a wide study performed in the UK over 4 years on centralized injectable preparation units (43 pharmacies) found a 0.49 % error rate (23) . The main cause can be related to the human individual error.
Because of the complexity of the manual process, more than 50 different drugs simultaneously prepared each day in the same controlled area, with multiple handling actions (i. e. injection, transfer, dilution), the human errors are utmost possible. Furthermore, the inappropriate re-use of single use device is very difficult to detect during the process of preparation and may be enough frequent to be problematic. In our study we did not investigate "closed transfer devices" (10) in that case, the risk of reuse of the withdrawal device is theoretical. In fact, withdrawal device used in place of needle or spike is permanently connected Rc = Vt x Cc Where Rc (mg) is the cross-contamination rate extrapolated for a given cytotoxic drug; Vt (mL) is the average volume of crosscontamination of the tracer experimentally found. Vt of thiamine or Vt of Retinol will be used function of the hydrophilic character of the cytotoxic drug; Cc (mg/mL) is the concentration of the commercialized solution of the cytotoxic drug. 
S: Significant; NS: Not significant; NA: Not applicable; LQ: Limit of quantification. to the vial and cannot be reused, however one can expect that the improper reuse of the syringe is still possible and will lead to the same risk. The cross-contamination rate found with the tracers when extrapolated to cytotoxic drugs can give significant rate of contamination.
We clearly noticed a difference of rate of contamination between lipophilic tracer and the hydrophilic one. The difference may be explained by the possible interactions of the lipophilic drug with the surface of plastic devices as previously described for carmustine (24) , or possible adsorption of cytotoxics on the filter of spikes (25) . Moreover, the process can introduce variability of the rate of cross-contamination depending on the lipophilic characteristic of the drug. With the usual process, syringes are systematically flushed five times to ensure homogenization of the preparation. To assess the impact of flushing syringes on cross-contamination, a complementary experiment was carried out without flushing. The lack of flushing was showing a significant impact (p < 0.001) on cross-contamination in comparison to flushing condition with a much higher contamination rate of 30.6 µl versus 2.4 µl and 17.3 µl versus 1.1 µl for retinol and thiamin respectively. Moreover, for both tracers, the inappropriate re-use of the spike was higher than needle, which can be easily explained by the higher dead volume in spike in comparison to needle. In summary, the process, the device and the chemical characteristic of the drug would affect the rate of cross-contamination.
Then the question is to know if the contamination observed may have consequences for the patient. According to the GMP for the cleaning validation (26) and applying the formulae used in industry published by Fourman and Mullen (27) with the criterion limit of 10 ppm, it can be found that the maximum admissible residue may be exceeded.
However, these limits do not take into account the available pharmacological and toxicological data. According to current regulatory practice it is assumed that genotoxic compounds have the potential to damage DNA at any level of exposure and that such damage may lead to tumour development (28, 29) . For genotoxic active substances for which there are no discernible thresholds, it is considered that any level of exposure carries a risk. However, a pre-defined level of acceptable risk for nonthreshold related genotoxics has been established in the form of the Threshold of Toxicological Concern (TTC) of 1.5 µg/person/day. With these thresholds, the risk exists for almost all preparations.
Thus the guidelines (21, 30) which recommended to separate the preparation of cytotoxic drugs from others injectable treatments such as monoclonal antibodies or at a minimum to work using segregated preparation by campaign seems to be fully justified.
Conclusion
In conclusion, external surface contamination seems to have little impact on the risk of cross-contamination but in contrast, the manual process can lead to errors of re-use of medical devices. Such errors present low or no detectability and can potentially have consequences for the patient. It is therefore important to find ways to minimize this risk, in particular separated areas for cytotoxic drug preparation. Automation and batch production would be interesting perspectives to limit the human error risk.
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